Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

18.9%

192 terminated/withdrawn out of 1017 trials

Success Rate

72.9%

-13.7% vs industry average

Late-Stage Pipeline

7%

67 trials in Phase 3/4

Results Transparency

34%

175 of 516 completed trials have results

Key Signals

124 recruiting175 with results123 terminated69 withdrawn

Enrollment Performance

Analytics

N/A
499(60.9%)
Phase 2
135(16.5%)
Phase 1
105(12.8%)
Phase 4
44(5.4%)
Phase 3
23(2.8%)
Early Phase 1
13(1.6%)
819Total
N/A(499)
Phase 2(135)
Phase 1(105)
Phase 4(44)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1017)

Showing 20 of 1017 trials
NCT07259304Active Not Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

Role: lead

NCT00183898Phase 2Completed

Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer

Role: lead

NCT07244211Not ApplicableRecruiting

MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)

Role: lead

NCT05312229Phase 1Recruiting

Housing Transitions QUERI

Role: collaborator

NCT07173803Phase 2Not Yet Recruiting

The Progressive Supranuclear Palsy Clinical Trial Platform

Role: collaborator

NCT06419985Phase 2Suspended

Ketamine HCl Prolonged Release Oral Tablets for CRPS

Role: lead

NCT06496867Not ApplicableRecruiting

Early Internal Fixation Versus NonOperative Care With Early Rehabilitation for LC1 Fragility Fractures of the Pelvis

Role: lead

NCT07721883Not ApplicableRecruiting

Social Media Influences on Engagement and Susceptibility to Non-combustible Tobacco Product Use Among Youth and Young Adults (AYA)

Role: lead

NCT07282821Phase 2Not Yet Recruiting

Bempedoic Acid Therapy for Polycystic Kidney Disease

Role: collaborator

NCT07129473Phase 1Recruiting

Hyperemesis Gravidarum Risk Reduction With Metformin

Role: lead

NCT07719205Not ApplicableRecruiting

Tactile Pre-Visit Imagery

Role: lead

NCT07694739Not ApplicableNot Yet Recruiting

E-cigarette Social Media Marketing and Its Perceptions by Youth

Role: lead

NCT07229443Not ApplicableActive Not Recruiting

CoGENES Randomized Controlled Trial (RCT)

Role: lead

NCT04446611Not ApplicableCompleted

Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes (Philani Ndiphile)

Role: collaborator

NCT07602699Phase 2Recruiting

Multi-Site Trial of Tirzepatide for Smoking Cessation

Role: lead

NCT05701657Not ApplicableRecruiting

Nutrition for Precision Health, Powered by the All of Us

Role: collaborator

NCT07698470Not ApplicableRecruiting

Brain/Craving Response to Smoking Cues After Oral Nicotine Pouch Use

Role: lead

NCT06506162Not ApplicableRecruiting

Abuse Liability and Appeal of Oral Nicotine Products

Role: lead

NCT02935361Phase 1Active Not Recruiting

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Role: lead

NCT01873326Phase 2Active Not Recruiting

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

Role: collaborator